The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the
subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant …

Major depression is a chronic illness where almost 30%–40% of patients do not respond to
conven-tional antidepressants, and for those who do, time to respond is often delayed for …

Major depressive disorder (MDD) is a psychiatric illness that can jeopardize the normal
growth and development of adolescents. Approximately 40% of adolescent patients with …

Introduction and aims Treatment-resistant depression (TRD) occurs when at least two
different antidepressants, taken at the right dosage, for adequate period of time and with …

This chapter focuses on the third‐generation antipsychotic cariprazine, from its molecular
pharmacology profile to clinical effects. We link the structural features of this bitopic drug with …